| Mgmt Confidence | High confidence in dual-mechanism synergy and rapid adoption by retinal specialists. |
|---|---|
| Capex & Debt | Second tranche of $95 million PIPE due upon IND opening. |
| Regulatory | IND filed 8-9 days ago; PTAB declined Merck's post-grant review challenge. |
| Commentary | Pioneering Wnt-based therapeutics to address 40% suboptimal response in current treatments. |
| New Launches | SCN-8141 entering clinic; SCN-8143 and SCN-113 in development pipeline. |
Growth
Targeting a $15 billion global anti-VEGF market with aging-related demand growth.
Outlook
Expects $95 million PIPE tranche; SCN-8141 data in 2H 2027.
Risks
Clinical data for lead candidate SCN-8141 not expected until second half of 2027.
The company's earnings call, NASDAQ: SRZN, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Surrozen, Inc.: key numbers
- Share price
- $32.32Close, Nov 16
- Market cap
- $616M
- Shares outstanding
- 19.06MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Surrozen, Inc.
All →Surrozen Capital Raise of $60M
Surrozen, Inc. entered into an underwriting agreement for a public offering of 1,894,540 shares of common stock at a price of $31.67 per share. The company expects to receive gross proceeds of approximately $60 million from the offering, which is scheduled to close on November 16, 2026.
- Value
- $60M
- Counterparty
- Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co.
Surrozen Q3 2026 Results: Net Loss of $130M, Loss Widens
Surrozen, Inc. reported a net loss of $207.1 million for the nine months ended September 30, 2026, significantly higher than the $58.9 million loss in the prior year period, primarily driven by a $111.5 million loss on the change in fair value of tranche liabilities. Total revenue for the nine-month period was $10.0 million, derived from collaboration and license revenue, while operating expenses increased to $48.5 million due to higher research and development costs.
- Key figure
- Net loss $130M
Surrozen Financial Results
Surrozen reported Q3 2026 financial results and announced the expansion of its Phase 2a DUET study for SZN-8141 from 60 to 150 patients. The company strengthened its balance sheet in October 2026 by closing a $95.1 million private placement tranche and raising $29.8 million via its ATM program, extending its cash runway into 2029.
- Term
- Q3 2026
“We have made important progress advancing Surrozen into its next stage of development, with the first patient dosed in the SZN-8141 DUET study and plans to significantly expand Phase 2a enrollment from approximately 60 to 150 patients. The additional capital raised in October positions us to generate a more robust clinical dataset across a broader DME population, while maintaining anticipated cash runway into 2029.”
Craig Parker, President and Chief Executive Officer
Surrozen Earnings Call: Key Takeaways
Surrozen is transitioning to a clinical-stage company with a $15 billion market opportunity, leveraging a $95 million financing tranche triggered by its IND filing for lead candidate SCN-8141 in diabetic macular edema.
Surrozen Capital Raise of $95.1M
Surrozen completed the second and final tranche of a private placement, raising approximately $95.1 million in gross proceeds. The closing was triggered by the achievement of a milestone involving FDA clearance of the IND application for SZN-8141. The funding is expected to provide a cash runway into 2029 to advance the company's ophthalmology pipeline through clinical milestones.
- Value
- $95.1M
“The completion of this financing marks an important milestone for Surrozen, significantly strengthening our balance sheet and providing the resources to advance our ophthalmology pipeline through multiple important clinical milestones.”
Craig Parker, President and Chief Executive Officer
“With expected cash runway into 2029, we are well positioned to advance SZN-8141 into the DUET Phase 1b/2a study and initiate clinical development of SZN-8143, while maintaining a disciplined approach to capital allocation.”
Craig Parker, President and Chief Executive Officer
Surrozen Capital Raise of $95.1M
Surrozen announced that the FDA clearance of its IND application for SZN-8141 triggered a second closing milestone under a previously announced private placement. This second tranche is expected to provide approximately $95.1 million in gross proceeds on or about October 20, 2026, to support clinical development and operations.
- Value
- $95.1M